AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...
分析师评论了Denali最近的股价下跌，将其归因于更广泛的市场趋势，而非公司特定消息。Denali的股价回调反映了XBI生物技术指数的走势，被认为是整体投资组合定位转变的一部分，在高利率环境下，较大的基金可能减少了生物技术领域的敞口。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback